Onconetix appoints Thomas Meier to board per Series B preferred holders' right

Onconetix, Inc.

Thomas Meier, PhD appointed as Class I director, term through 2025 annual meeting.
Meier has 25+ years biotech experience; chairs Santhera Pharmaceuticals (SIX:SANN).
Consulting agreement: CHF 400/hr as sellers' rep (Proteomedix deal) and CHF 350/hr as advisor.
Appointment effective Feb 6, 2024; ratified by Audit Committee Feb 8, 2024.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Thomas Meier

Director

ONCO · Onconetix, Inc.

Effective: 2024-02-06
Filed: February 12, 2024, 6:59 PM ET

On February 6, 2024, pursuant to the Certificate of Designation of Series B Convertible Preferred Stock, the holders of Series B Convertible Preferred Stock appointed Thomas Meier, PhD, to the board of directors of Onconetix, Inc. (the “ Company ”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Thomas Meier was appointed as Director at Onconetix, Inc..

Action: appointed
Role: Director

Exact text from the filing

On February 6, 2024, pursuant to the Certificate of Designation of Series B Convertible Preferred Stock, the holders of Series B Convertible Preferred Stock appointed Thomas Meier, PhD, to the board of directors of Onconetix, Inc. (the “ Company ”).

View on SEC.gov

Onconetix, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-24-012608

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.